BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11299694)

  • 21. Charting your company's future.
    Kim WC; Mauborgne R
    Harv Bus Rev; 2002 Jun; 80(6):76-83, 153. PubMed ID: 12048996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ending the CEO succession crisis.
    Charan R
    Harv Bus Rev; 2005 Feb; 83(2):72-81, 147. PubMed ID: 15724575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to grow great leaders.
    Ready DA
    Harv Bus Rev; 2004 Dec; 82(12):92-100, 149. PubMed ID: 15605569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surviving your new CEO.
    Coyne KP; Coyne EJ
    Harv Bus Rev; 2007 May; 85(5):62-9, 142. PubMed ID: 17494251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ambidextrous organization.
    O'Reilly CA; Tushman ML
    Harv Bus Rev; 2004 Apr; 82(4):74-81, 140. PubMed ID: 15077368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The five messages leaders must manage.
    Hamm J
    Harv Bus Rev; 2006 May; 84(5):114-23, 158. PubMed ID: 16649703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Creating corporate advantage.
    Collis DJ; Montgomery CA
    Harv Bus Rev; 1998; 76(3):70-83. PubMed ID: 10179655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A time for growth: an interview with Amgen CEO Kevin Sharer. Interview by Paul Hemp.
    Sharer K
    Harv Bus Rev; 2004; 82(7-8):66-74, 186. PubMed ID: 15241953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why entrepreneurs don't scale.
    Hamm J
    Harv Bus Rev; 2002 Dec; 80(12):110-5, 134. PubMed ID: 12510543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Learning organizations: an introduction.
    Dowd JF
    Manag Care Q; 1999; 7(2):43-50. PubMed ID: 10537639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-market innovation.
    Rigby D; Zook C
    Harv Bus Rev; 2002 Oct; 80(10):80-9, 129. PubMed ID: 12389463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leading change when business is good. Interview by Paul Hemp and Thomas A. Stewart.
    Palmisano S
    Harv Bus Rev; 2004 Dec; 82(12):60-70, 148. PubMed ID: 15605566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Welcome aboard (but don't change a thing).
    McNulty E
    Harv Bus Rev; 2002 Oct; 80(10):32-5; discussion 36-40, 127. PubMed ID: 12389459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Fidelity invests in service professionals.
    McColgan EA
    Harv Bus Rev; 1997; 75(1):137-43. PubMed ID: 10174451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rebuilding the R&D engine in big pharma.
    Garnier JP
    Harv Bus Rev; 2008 May; 86(5):68-70, 72-6, 128. PubMed ID: 18543809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The passive-aggressive organization.
    Kaplan RS; Norton DP
    Harv Bus Rev; 2005 Oct; 83(10):82-92, 157. PubMed ID: 16250627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What's needed next: a culture of candor.
    O'Toole J; Bennis W
    Harv Bus Rev; 2009 Jun; 87(6):54-61, 113. PubMed ID: 19496471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Who owns the long term? Perspectives from global business leaders.
    Lévy M; Eskew M; Bernotat WH; Barner M
    Harv Bus Rev; 2007; 85(7-8):54-60, 191. PubMed ID: 17642126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selling the brand inside.
    Mitchell C
    Harv Bus Rev; 2002 Jan; 80(1):99-101, 103-5, 126. PubMed ID: 12964471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Building a leadership brand.
    Ulrich D; Smallwood N
    Harv Bus Rev; 2007; 85(7-8):92-100, 192. PubMed ID: 17642128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.